Literature DB >> 18160304

Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome.

Giuseppe Malleo1, Emanuela Mazzon, Tiziana Genovese, Rosanna Di Paola, Rocco Caminiti, Emanuela Esposito, Placido Bramanti, Salvatore Cuzzocrea.   

Abstract

Experimental evidence suggests that interleukin (IL)-10 plays a pivotal role in generalized inflammation. Here we investigate the effects of IL-10 gene deletion on the acute phase of the multiple organ dysfunction syndrome (MODS) caused by zymosan in the mouse. MODS was induced by zymosan administration (500 mg/kg, suspended in saline solution, i.p.) in IL-10 wild-type and knockout mice; sham groups were treated with vehicle. Mice were sacrificed 18 h after zymosan or saline administration. In another set of experiments, animals were monitored for 12 days to assess systemic toxicity and survival rate. Mice lacking IL-10 displayed increased peritoneal exudate volume and leukocytes. Also, we observed a significant increase in myeloperoxidase activity and lipid peroxidation in ileum and lung tissues, as well as augmented levels of TNF-alpha, IL-1beta and nitrogen-derived species in the plasma. With regard to organ injury, absence of IL-10 enhanced the renal, hepatocellular and pancreatic dysfunction caused by zymosan administration. All of these parameters significantly influenced the systemic toxicity and the overall survival at 12 days, which was significantly lower in IL-10 knockout mice. Therefore, this study demonstrates that the absence of endogenous IL-10 enhances the MODS induced by zymosan in mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160304     DOI: 10.1016/j.cyto.2007.11.003

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Direct hemoperfusion with a polymyxin B-immobilized cartridge in intestinal warm ischemia reperfusion.

Authors:  Hiroaki Sato; Kiyohiro Oshima; Kazuhisa Arakawa; Katsumi Kobayashi; Hodaka Yamazaki; Yujin Suto; Izumi Takeyoshi
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-γ, TNF-α, MIP-1β, G-CSF, and MCP-1β.

Authors:  R Prondzinsky; S Unverzagt; H Lemm; N Wegener; K Heinroth; U Buerke; M Fiedler; J Thiery; J Haerting; K Werdan; M Buerke
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-07-20       Impact factor: 0.840

3.  2-Polyunsaturated acyl lysophosphatidylethanolamine attenuates inflammatory response in zymosan A-induced peritonitis in mice.

Authors:  Nguyen Dang Hung; Mee Ree Kim; Dai-Eun Sok
Journal:  Lipids       Date:  2011-07-10       Impact factor: 1.880

4.  Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine.

Authors:  Nguyen Dang Hung; Dai-Eun Sok; Mee Ree Kim
Journal:  Inflamm Res       Date:  2012-01-18       Impact factor: 4.575

5.  Repeated Stimulation of Toll-Like Receptor 2 and Dectin-1 Induces Chronic Pancreatitis in Mice Through the Participation of Acquired Immunity.

Authors:  Masahiro Takeo; Akiyoshi Nishio; Masataka Masuda; Kazunori Aoi; Takashi Okazaki; Toshiro Fukui; Kazushige Uchida; Makoto Naganuma; Kazuichi Okazaki
Journal:  Dig Dis Sci       Date:  2021-08-23       Impact factor: 3.487

6.  Continuous blood purification ameliorates clinical signs and corrects the plasma phospholipid levels of patients with multiple organ dysfunction syndromes.

Authors:  Wei Wen; Kun Wang; Zhi-Ming Jiang; Zhong-Hui Zhang; Lei Zhou
Journal:  J Clin Lab Anal       Date:  2018-02-18       Impact factor: 2.352

7.  Inhalative IL-10 attenuates pulmonary inflammation following hemorrhagic shock without major alterations of the systemic inflammatory response.

Authors:  Philipp Kobbe; Philipp Lichte; Helen Schreiber; Lucy Kathleen Reiss; Stefan Uhlig; Hans-Christoph Pape; Roman Pfeifer
Journal:  Mediators Inflamm       Date:  2011-10-20       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.